source
- AbbVie pays $100M upfront in $1.4B deal for Nxera's phase-1 IBD candidateAbbVie has agreed to pay $100 million upfront for the worldwide rights to Nxera's oral EP4 receptor agonist, designated NXE0033744, with the total deal value potentially reaching $1.4 billion throu…
- Ultragenyx to cut 20% of staff and halve R&D budget as it pivots to commercial salesUltragenyx announced it will reduce its workforce by about 20%, bringing headcount down to roughly 1,000 employees. The cuts follow an earlier 10% reduction announced in February and are part of a…